SCHEMBL2998940

SCHEMBL2998940

C=C(C)C(=O)NCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.31
GBA1 P04062 2/20 0.31
THRB P10828 1/20 0.31
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12199962 1.00 CA2 (0.31) CA2GBA1THRBCA1
SCHEMBL12199997 0.98 GBA1 (0.30) GBA1
SCHEMBL12200553 0.89 GBA1 (0.36) CA2GBA1
SCHEMBL8729672 0.86 TGFBR1 (0.32)
SCHEMBL12200561 0.86 MEN1 (0.37) CA2GBA1
SCHEMBL12200560 0.83 CA2 (0.41) CA2THRB
SCHEMBL1093362 0.81 GBA1 (0.30) GBA1
SCHEMBL13146825 0.81 CA2 (0.39) CA2
SCHEMBL21504381 0.78 TGFBR1 (0.33)
SCHEMBL10339278 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226814-A1 ON-PRESS DEVELOPMENT TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR, METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE, AND LITHOGRAPHIC PRINTING METHOD FUJIFILM CORPORATION (JP) 2023-07-20 US disclosed
US-10087273-B2 Multifunctional polymers ISP INVESTMENTS LLC (US) 2018-10-02 US disclosed
US-10010502-B2 Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation AMORPHEX THERAPEUTICS LLC (US) 2018-07-03 US disclosed
WO-2016187426-A1 A DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG AMORPHEX THERAPEUTICS LLC (US) 2016-11-24 WO disclosed
US-20160338947-A1 DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG, WHILE PRESERVING PUPILLARY FUNCTION AND ACCOMMODATION AMORPHEX THERAPEUTICS LLC 2016-11-24 US disclosed
US-20150044161-A1 MULTIFUNCTIONAL POLYMERS ISP INVESTMENTS INC. (US) 2015-02-12 US disclosed
US-20110242654-A1 Hardcoat layer-forming composition, optical film, production method of optical film, polarizing plate and image display device FUJIFILM CORPORATION (JP) 2011-10-06 US disclosed
US-20110242191-A1 INK COMPOSITION, INKJET RECORDING METHOD AND PROCESS FOR PRODUCING MOLDED PRINTED MATERIAL FUJIFILM CORPORATION (JP) 2011-10-06 US disclosed
US-20100178315-A1 POLYMERIC SYSTEMS FOR CONTROLLED DRUG THERAPY VISTA SCIENTIFIC LLC (US) 2010-07-15 US disclosed
US-20060198892-A1 Polymeric systems for controlled drug therapy AMORPHEX THERAPEUTICS LLC 2006-09-07 US disclosed
EP-1656116-A2 POLYMERIC SYSTEMS FOR CONTROLLED DRUG THERAPY Vista Scientific LLC (US) 2006-05-17 EP disclosed
WO-2005023181-A2 POLYMERIC SYSTEMS FOR CONTROLLED DRUG THERAPY VISTA SCIENTIFIC (US) 2005-03-17 WO disclosed
US-20040247681-A1 Drug release system for controlled therapy VISTA SCIENTIFIC LLC 2004-12-09 US disclosed
EP-0425436-B1 Reactive silicone and/or fluorine containing hydrophilic prepolymers and polymers thereof CIBA GEIGY AG (CH) 1996-12-27 EP disclosed
US-5079319-A Contact Lenses CIBA-GEIGY CORPORATION (US) 1992-01-07 US disclosed
EP-0425436-A2 Reactive silicone and/or fluorine containing hydrophilic prepolymers and polymers thereof CIBA-GEIGY AG (CH) 1991-05-02 EP disclosed
US-5010141-A Heat- or UV-curable acrylic resins; coatings; films; biocompatible, water-swelling, oxygen-permeable contact lenses CIBA-GEIGY CORPORATION (US) 1991-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160338947-A1 DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG, WHILE PRESERVING PUPILLARY FUNCTION AND ACCOMMODATION MYOC, STRA6, MYOF CA2 531/4885GBA1 3238/4885THRB 2774/4885
US-10010502-B2 Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation MYOC, STRA6, MYOF CA2 531/4885GBA1 3238/4885THRB 2774/4885
US-20060198892-A1 Polymeric systems for controlled drug therapy PAICS, ABCB1, CES2 CA2 2124/4885GBA1 2007/4885THRB 3542/4885
US-20150044161-A1 MULTIFUNCTIONAL POLYMERS PUF60, PARG, PARN CA2 3586/4885GBA1 2912/4885THRB 4562/4885
US-10087273-B2 Multifunctional polymers PUF60, PARG, PARN CA2 3586/4885GBA1 2912/4885THRB 4562/4885
US-20100178315-A1 POLYMERIC SYSTEMS FOR CONTROLLED DRUG THERAPY PAICS, ABCB1, CES2 CA2 2124/4885GBA1 2007/4885THRB 3542/4885
US-20040247681-A1 Drug release system for controlled therapy FKBP2, FKBP3, FKBP1B CA2 3804/4885GBA1 3597/4885THRB 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.